The median survival time and 2-year survival rate were significantly lower in patients with SMARCA4-UT than in patients with undifferentiated thoracic tumors that retained SMARCA4 (mOS: 4 vs 39.9 months; 2-year survival rate: 12.5% vs 64.4%). Here, SMARCA4 is linked to neoplasm of thorax.